Britain to study weight loss drug's potential to get people back to work
Britain is set to explore the potential of Eli Lilly's weight loss drug to improve public health and economic productivity by reducing long-term sickness. Health minister Wes Streeting believes this initiative, supported by substantial investment and research, could significantly impact obesity management and alleviate NHS demands. Key Points
India TodayDubai, London links uncovered in Rs 5,000-crore drug bust in Delhi
Virendra Basoya runs a big drug network from Dubai. Last year, Pune Police seized the Meow Meow drug worth Rs 3,000 crores and Basoya's name also surfaced in that case too. Key Points
India Todaydrug for pancreatic cancer shows promise against brain tumour in kids
New Delhi, August 2 A drug that was developed to treat pancreatic cancer has shown promise to treat medulloblastoma—the most common malignant brain tumour in children. In the study, published in the Journal of Clinical Investigation, the drug triptolide, which... Key Points
The TribuneCan Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?
Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynichs $25 billion potential counters global antibiotic resistance. Key Points
Economic TimesAlzheimer’s drug that can slow disease gets backing from FDA advisers
Donanemab to only be the second Alzheimer’s drug cleared in the US to convincingly slow cognitive decline. Closely watched Alzheimer’s drug from Eli Lilly... Key Points
The Tribune India
Latest safety alert on painkiller nimesulide brings focus back on potentially dangerous side effect
Drug standards body warns that nimesulide, a commonly used painkiller and anti-fever medicine, can cause skin rashes. However, evidence has also emerged that it can cause liver damage. Key Points
ThePrintCops find 'meow meow' drug worth Rs 3,500 crore during raids in Delhi, Pune
Police have seized 1,800 kg of synthetic stimulant drug mephedrone, also known as 'Meow Meow', estimated to be worth around Rs 3,500 crore, following massive raids in Pune and Delhi. Six people have been arrested. Key Points
India TodayIPC alert advises patients to monitor possibility of mefenamic acid's adverse effects: Meftal makers
'The alert issued by IPC was to advise doctors and patients to monitor the possibility of an adverse drug reaction of mefenamic acid, which does not in any way impact the safety, efficacy and high quality of the brands that are established and supported by clinical... Key Points
The Tribune IndiaDr Reddy's recalls over 8,000 bottles of generic drug in US due to packaging error
Dr Reddy's Laboratories is recalling over 8,000 bottles of Tacrolimus capsules from the US market due to a packaging error. The Hyderabad-based drug major has already recalled 4,000 bottles of the same medication in March 2023. The recall is a Class II recall, initiated on December 15, 2023, due to potential adverse health consequences or a low probability of serious adverse health effects. Key Points
Economic TimesHashish worth Rs 1.04 crore seized in Mumbai, 6 including Kashmir resident held
Mumbai Police's Anti-Narcotics Cell (ANC) busted an interstate drug racket in the city and seized a huge cache of contraband. Six people have been arrested in the recovery of illegal substances. Key Points
India Today/cloudfront-us-east-2.images.arcpublishing.com/reuters/OAYYXJV7MFNPRFTBFUEG4CYWVI.jpg)
Eisai to launch Alzheimer's drug Leqembi in Japan on Dec 20
Eisai (4523.T) said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Key Points
Reuters‘Promising’ anti-ageing drug for large-breed dogs to gain FDA approval soon
Good news for all the pet owners! A ‘promising’ anti-ageing drug for large breed dogs is nearing approval from the FDA. Read more below. Key Points
Hindustan TimesIndia's Dr. Reddy's shares fall on observations from US regulator
BENGALURU (Reuters) - Shares of Indian drug-maker Dr. Reddy's Laboratories were down 6.5% on Monday after the U.S. Food and drug Administration issued three observations for the company's plant in Key Points
ThePrintGovernment alerts on Meftal; all about adverse reaction the painkiller can cause
Government has issued alert about an adverse reaction of Meftal. The syndrome causes a diverse array of symptoms, from 2 to 8 weeks after initiating the drug. | Health Key Points
Hindustan TimesSpecial Report: Udta Punjab now gets hooked on de-addiction drugs
Punjab, which is dealing with a massive drugs and alcohol addiction problem, has a new problem at hand. Addicts at de-addiction centres are getting hooked on de-addiction drugs. This comes after seizures increased the street cost of drugs. Key Points
India Today/cloudfront-us-east-2.images.arcpublishing.com/reuters/UZARREKRAZPXHEQHO64ZDLWDII.jpg)
Merck KGaA suffers major blow as MS drug fails in late-stage trials
Germany's Merck KGaA (MRCG.DE) said its experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials, dealing a major blow to the company's growth ambitions. Key Points
ReutersAltimmune open to partnerships, deals with drugmakers, says CEO
Weight-loss drug developer Altimmune (ALT.O) is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg told Reuters on Tuesday. Key Points
ReutersEli Lilly's obesity drug now available in U.S. pharmacies
Eli Lilly's (LLY.N) recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost customers whose health insurance does not cover the drug $550 a month, or half the list price, the company said on Tuesday. Key Points
ReutersRoche enters obesity drugs race with $2.7 bln Carmot deal
The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O). Key Points
ReutersEU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts
The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's (NOVOb.CO) popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them. Key Points
Reuters/cloudfront-us-east-2.images.arcpublishing.com/reuters/LTWSDI6PKRO57BSYQSRPDALZDM.jpg)
Pfizer drops twice-daily version of obesity pill over side effects
Pfizer (PFE.N) said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting, and its shares fell 5%. Key Points
ReutersUS FDA gives second approval to Eli Lilly's drug for type of blood cancer
Eli Lilly (LLY.N) said on Friday the U.S. Food and drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer. Key Points
Reutersdrug regulator initiates move to control tapentadol & pregabalin sale amid reports of growing misuse
India's apex drug regulator will form a panel to examine whether more regulatory restrictions should be put in place. Experts say more curbs a good idea but implementation is key. Key Points
ThePrintCanadian drugmaker Xenon Pharma's depression drug fails to meet main study goal
Canada's Xenon Pharmaceuticals (XENE.O) said on Monday its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study. Key Points
ReutersGSK says blood cancer drug meets primary goal in late-stage trial
British drugmaker GSK (GSK.L) said on Monday its blood cancer drug Blenrep, when used as a second-line treatment in patients with myeloma, met its primary goal of progression-free survival in a late-stage trial. Key Points
Reuters/cloudfront-us-east-2.images.arcpublishing.com/reuters/7HD6P27M3VN2FPAJVC4ZXNYOKQ.jpg)
Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win
Sanofi (SASY.PA) plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits. Key Points
ReutersBayer recalls one lot of cancer drug Vitrakvi due to contamination
Bayer (BAYGn.DE) said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination. Key Points
ReutersUS FDA approves Bristol-Myers' lung cancer drug
The U.S. Food and drug Administration (FDA) has approved Bristol-Myers Squibb's (BMY.N) lung cancer drug that was acquired as part of the company's $4.1 billion buyout of Turning Point Therapeutics last year. Key Points
ReutersGerman drug regulator considering export ban on Ozempic
The head of German drug regulator BfArM is considering an export ban on Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a worsened supply shortage. Key Points
ReutersEli Lilly: still seeking UK approval on pen for weight-loss drug
Eli Lilly (LLY.N) on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch. Key Points
Reuters/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYKY5TU5CRNZPF75PEOHCTMUAQ.jpg)
AstraZeneca raises stakes in obesity drug race with Eccogene deal
AstraZeneca (AZN.L) moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field. Key Points
ReutersWhat to know about Eli Lilly's new obesity drug
The U.S. Food and drug Administration approved Eli Lilly's (LLY.N) keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's (NOVOb.CO) popular weight-loss therapy Wegovy. Key Points
ReutersTirzepatide approved for weight loss, stronger than semaglutide
Mounjaro is a stronger drug than Ozempic. Now, there's a version of the drug available for patients who aren't diabetic. Key Points
InsiderWhole genome sequencing personalising TB therapy, ensuring complete treatment: Expert
TB is an infectious disease that spreads through the medium of air when people with lung TB cough, sneeze, or spit.. A new technique that uses whole genome sequencing can help personalise drug therapy in tuberculosis (TB) patients and ensure complete treatment for the disease, according to a biotechnologist. Anirvan Chatterjee, founder & CEO of HaystackAnalytics, a start-up incubated at the Indian Instit Key Points
The Tribune IndiaBTS' agency denies members visiting establishment linked with drug case
Reports claim two BTS Members frequently visited the bar where G-Dragon and Lee Sun Kyun allegedly used drugs. The matter is being investigated. Key Points
Hindustan Times/cloudfront-us-east-2.images.arcpublishing.com/reuters/NJ3BXQ4COJNL5CC4TPKJQ2X3QE.jpg)
Novartis lifts 2023 earnings forecast for third time
Switzerland's Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for a multiple sclerosis (MS) drug. Key Points
ReutersLilly's bowel disease drug gets US FDA nod for treatment in adults
Eli Lilly and Co (LLY.N) said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. Key Points
ReutersSanthera's drug gets US FDA nod for rare muscular dystrophy
Catalyst Pharmaceuticals (CPRX.O) said on Thursday that U.S. health regulators have approved its partner Santhera Pharmaceuticals' (SANN.S) drug to treat Duchenne muscular dystrophy (DMD) in patients aged two years and older. Key Points
ReutersG-Dragon breaks silence in alleged scandal, denies drug use
G-Dragon has been reportedly booked for alleged drug charges. Parasite actor Lee Sun Kyun was booked as well but in a different drug case, as per reports. Key Points
Hindustan TimesPTC Therapeutics announces job cuts to lower annual operating expenses
PTC Therapeutics (PTCT.O) said on Thursday it plans to cut 25% of its workforce, as the drugmaker aims to reduce its yearly operating expenses. Key Points
Reuters
Structure Therapeutics surges on promising early stage obesity drug data
Shares of Structure Therapeutics (GPCR.O) soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study. Key Points
ReutersIonis' metabolic disorder drug lowers high levels of a type of fat in study
Ionis Pharmaceuticals (IONS.O) said on Tuesday its experimental drug met the main goal of reducing abnormally high levels of the most common type of body fat in a late-stage trial in patients with a metabolic disorder. Key Points
ReutersImmunovant shares surge after antibody treatment succeeds in early-stage study
Shares of Immunovant (IMVT.O) surged over 60% in premarket trading on Tuesday, after data from an early-stage study showed the drug developer's experimental treatment helped reduce levels of an inflammation-causing antibody in healthy adults. Key Points
ReutersJ&J, India's Lupin cut prices for tuberculosis drug in lower-income countries
Johnson & Johnson (JNJ.N) and Indian drugmaker Lupin (LUPN.NS) will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday. Key Points
ReutersMann's I-Day speech brings drug abuse back in focus: CM seeks 1 yr to end menace, Oppn attacks 'lies'
CM Bhagwant Mann promises Punjab will be drug-free by next Independence Day. Oppn says AAP's poll promise was to eradicate drug abuse within 3-4 months of coming to power. Key Points
ThePrintWegovy reduces risk of heart attacks, strokes, and death by up to 20%, new study finds
A large global study found that weight-loss drug Wegovy reduced the risk of major cardiovascular issues. It could prompt insurers to cover the drug. Key Points
InsiderFDA approves first postpartum depression pill
The FDA has approved a pill, Zurzuvae, to treat severe depression after childbirth, a condition that affects thousands of new mothers in the US each year. Postpartum depression affects an estimated 400,000 people a year, and while it often ends on its own within a couple of weeks, it can continue for months or even years. The standard treatment includes counselling or antidepressants, which can take weeks to work and don't help everyone. Key Points
Economic Times